ADVANCING THE FIRST ACCOMMODATING

INTRAOCULAR LENS

INTRAOCULAR LENS

(AIOL)THAT REPLICATES NATURAL VISION

TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0

THE OPPORTUNITY

THE OPPORTUNITY

Breakthrough Innovation

  • Successful First-In-Human (FIH) implants – August 2025
  • Designed for rapid, dynamic focus – near to far in <1 second
  • Multiple global patents & patents pending

Strong Leadership

  • CEO Dean Burns: ex-Alcon Vision ($750M BU, 15 FDA approvals, $6B in product launches)
  • Backed by 12 leading ophthalmology advisors

Massive Market Opportunity

  • $4.5B+ global IOL market, growing 3–5% CAGR
  • Initial focus: $1.2B premium cataract segment (65+)
  • Expansion pipeline into larger adjacent markets

Industry Validation

  • 4 of top 7 global eyecare companies requested FIH results
  • Active M&A interest in next-gen vision correction technologies

Clear Roadmap To Commercialization (1)

  • 30-patient First-in-Human study (2025–26)
  • FDA multi-phase study (2026–28)
  • CE Mark & early EU commercialization (2027)

(1) Timeline estimates are subject to change

THE PROBLEM – SIGHT LOSS WITH AGE

THE PROBLEM – SIGHT LOSS WITH AGE

THE PROBLEM – SIGHT LOSS WITH AGE

The eye deteriorates as we age developing the following conditions:

  • Presbyopia (age 45+): Loss of accommodation – inability to focus
  • Cataracts (age 65+): Cloudy, inflexible natural – blindness if untreated

Existing solutions:

  • Glasses, contacts, fixed-focus implants – don’t restore natural vision.
Prevalence of Presbyopia in North America
  • Adults aged 45 and older in the U.S. experience presbyopia at very high rates—about 83%. *(1)
  • Presbyopia is an age-related decline in the eye’s ability to focus on near objects. In North America (particularly the U.S.), it’s nearly universal by age 45—affecting over four-fifths of adults in that age group. Given the U.S. population aged 45+, that translates to more than 120 million people experiencing difficulty with near vision. *(2)

* (1) https://eyesoneyecare.com * (2) https://www.presbyopiaphysician.com

THE SOLUTION – OCUMETICS LENS

THE PROBLEM – SIGHT LOSS WITH AGE

THE PROBLEM – SIGHT LOSS WITH AGE

OCUMETICS LENS OVERVIEW

  • Biometric Vision Restoration
    Replicates natural eye biomechanics using shape-changing lens technology, restoring life-like visual adaptability instead of static correction.
  • Instant Dynamic Focusing
    Shifts focus from near to far in under one second, ensuring seamless clarity for reading, driving, or distance viewing.
  • No Silicone Oil Chamber
    Avoids fragile silicone oil chambers used in competitor implants, preventing leakage, clouding, and long-term instability.
  • Minimized Post-Surgical Risks

    Eliminates common lens side effects like glare, halos, or secondary procedures, delivering safer recovery and better outcomes.
  • High-Quality Optics, Safe & Affordable

    Combines premium optics and strict safety with scalable production, keeping advanced vision correction accessible and affordable.

ACCOMMODATING IOL COMPETITION

ACCOMMODATING IOL COMPETITION

ACCOMMODATING IOL COMPETITION

TECHNOLOGY ANALYSIS

TECHNOLOGY ANALYSIS

TECHNOLOGY ANALYSIS

TechnologyDistanceIntermediateNearSide Effects

Monofocal

No 

EDOF

No

BifocalYes*
TrifocalYes*
Accommodating Ocumetics

No

* Side effects = Halos, ghosting, starbursts and light scatter

CORPORATE PRESENTATION

CORPORATE PRESENTATION

CORPORATE PRESENTATION

MARKET ANALYSIS

Ocumetics strategy is to initially enter the $1.2Bn, 65+ Cataract surgery segment

MANAGEMENT & DIRECTORS

MANAGEMENT & DIRECTORS

MANAGEMENT & DIRECTORS

TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0

Dean Burns

CEO, President  & Director

Former Senior Director at Alcon Vision, managing a $750M business unit across devices, disposables, intraocular lenses (IOLs), and pharmaceuticals. Successfully led 15 FDA approvals and 15 product launches with a combined $6B commercial value, while partnering with 12 of the leading global advisors in Ophthalmology.

Roger Jewett CA, CPA

CFO & Director

With over 25 years of experience leading public and private companies, he has guided organizations through financings, M&A, and growth, closing more than $70 million in financings and completing over 40 acquisitions and divestitures. His track record includes turning around companies such as Enerjet and RCR, scaling startups like Rare Method and Jump On Flyaways, and cofounding Quantum Blockchain Technologies, which later merged with Ocumetics.

Dr. Garth Webb

FOUNDER, CSO & Director

He is the Founder of Ocumetics and sole inventor of the Bionic Lens™ technology platform, bringing over 45 years of experience in clinical eye care, vision science, and refractive technology innovation. A proven entrepreneur, he co-founded one of Canada’s largest optometry clinics and launched multiple health science ventures. As a leader in advancing medical optics, his mission is to transform vision and enhance quality of life.

Dr. Doyle Stulting

CHIEF MEDICAL OFFICER & DIRECTOR

He is a renowned corneal surgeon and recognized global leader in cataract, refractive surgery, and transplantation. He has served as Principal Investigator in multiple FDA clinical trials, including groundbreaking studies in corneal cross-linking, and is a former Chair of the FDA Ophthalmic Devices Panel and Past President of the American Society for Cataract and Refractive Surgery.

Dr. James B McRoberts,O.D.

Director

With over 40 years of experience in optometry, including private practice in British Columbia, he has served as Past President of the BC Association of Optometrists and as Registrar of the BC College of Optometrists. His career includes leadership roles across professional boards, regulatory bodies, and laser vision centers, along with contributions as a published author and lecturer on optometry practice and policy.

Michael Edwards

Director

He is a Director at Pinnacle Wealth Brokers, one of Canada’s largest Exempt Market Dealers, and President of Customized Insurance & Tax Solutions, specializing in insurance and investment products. A Chartered Life Underwriter with extensive expertise in tax, finance, and estate planning, he brings a strong foundation of technical knowledge and practical experience. His board involvement spans private companies, industry associations such as the PCMA, and several major charitable organizations.

Robert Quinn

Director

He is an independent businessman with extensive board, management, and legal experience in the international mining industry. Skilled in corporate governance, environmental oversight, M&A, financing, contracts, compliance, and litigation, he has a proven track record supporting companies in mine development and global exploration programs. He holds a Juris Doctor degree from the University of Denver School of Law and a Bachelor’s in Business Administration from the University of Denver.

TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0

NEWS RELEASES

NEWS RELEASES

LATEST NEWS

HOW TO INVEST

TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO

If you don’t have a trading account, you can buy stock in Ocumetics with the following online brokers. Please click a logo and it will direct you on how to set up a trading account with your bank.

Clearly See The Opportunity

TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0